Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
Hemab Therapeutics (Nasdaq:COAG) reported new HMB-002 clinical data for von Willebrand disease at ISTH 2026, citing dose-dependent increases of VWF and FVIII, including ≥2.4-fold peaks in cohort A3 (150 mg), plus normalization of thrombin generation and APTT. It also announced HMB-003, a non-hormonal plasmin inhibitor targeting heavy menstrual bleeding.
How this was made
The 30-second read
Why it matters
The new HMB-002 data provide a fresh mechanistic and safety checkpoint that can improve perceived probability of success, while the HMB-003 announcement expands the pipeline narrative around non-hormonal antifibrinolysis.
Market read
For COAG, the article is a conference-driven catalyst with concrete mechanistic PK/PD and safety details for HMB-002, plus a pipeline expansion headline for HMB-003.
What to watch
No serious TEAEs and no thromboembolic events are encouraging, but the durability claim is based on PK/PD and a short observation window; investors may discount the impact until repeat-dosing and controlled efficacy data are available.
Background
Hemab is a clinical-stage biotech focused on coagulation disorders, with HMB-002 targeting von Willebrand disease via a non-replacement strategy and HMB-003 targeting heavy menstrual bleeding via plasmin inhibition.
Ticker impact
Hemab presented new HMB-002 VWD clinical data showing dose-dependent ≥2.4-fold VWF and FVIII increases and no serious TEAEs, plus announced HMB-003 for heavy menstrual bleeding.
Near-term upside bias possible on biotech-conference momentum, but magnitude likely capped until efficacy endpoints and later-stage data emerge.
The article discloses specific mechanistic PK/PD and safety observations for HMB-002, which are meaningful for a clinical-stage biotech. However, it explicitly states the SAD portion was not designed to measure efficacy, and HMB-003 is described with preclinical minipig data rather than human results.
Market effects
Supports investor appetite for non-replacement coagulation approaches and antifibrinolytic peptide platforms, but does not change the competitive landscape with new peer-specific data.
Limited, as the catalyst is company-specific at an international conference.
Moderate for global bleeding-disorder therapeutics sentiment, but no regulatory or market-wide datapoints are introduced.
Counterpoint
Mechanistic and safety signals may not translate into durable, clinically meaningful bleed reduction; the article’s efficacy observations are descriptive and from a SAD study not powered for endpoints.
Key entities
- companyHemab Therapeutics
Nasdaq-listed clinical-stage biotech presenting new HMB-002 data and introducing HMB-003 at ISTH 2026.
- programHMB-002
Non-replacement prophylactic antibody program for von Willebrand disease; presented dose-dependent VWF and FVIII increases and safety results.
- programHMB-003
Non-hormonal direct plasmin inhibitor peptide program for heavy menstrual bleeding; introduced with preclinical duration data.
